



IVI Director General Dr. Jerome Kim's remarks of appreciation for Donation Ceremony in honor of Prof. SUNG Young-chul

Prof. Sung Young Chul, and Mrs. Lee Okhee; Prof. Park Sang Chul, Dr. Rhee Byoung Geon, Prof. Cho Wankyoo, Prof. Park Sang Dai, Colleagues, and friends

On behalf of the International Vaccine Institute, I would like to express my deep gratitude to Prof. Sung and Mrs. Lee for their extraordinary contributions to IVI. Through their support for the KSC IVI's work of discovering, developing and delivering new vaccines can grow, taking on new challenges, and bringing the benefits of vaccination to more families around the world.

The donation of 10 billion won is the largest individual donation to IVI and represents leadership, vision, and compassion – we hope that this gift will provide inspiration to others and enable IVI to fulfill the dreams and expectations of its founders – Prof. Cho and Prof. Park – who have joined us for this ceremony.

It has never been easy to develop and deliver vaccines – but the benefits of vaccines are substantial and tangible. 2.5 million more children survive every year because of vaccination, and if we were able to vaccinate everyone fully, we would save an additional 2.5 million annually. But the benefits of vaccination – from improved growth, improved cognition, better education, lower poverty, accelerated economic development – can only be realized if vaccine R&D and vaccination programs are empowered. Thanks to this donation, we are given a greater capacity to make a difference for the good.



IVI's oral cholera vaccine, manufactured by Sanofi and Eubiologics, is the OCV stockpile and over 36 million doses have been used worldwide in locations where cholera outbreaks have occurred; the success of OCV has led UNICEF and WHO to announce a Roadmap to a 90% reduction in cholera deaths by 2030.

This donation will help with the prevention of a second disease, typhoid, through its support for vaccination campaigns in the Pacific and in Africa; IVI's own typhoid conjugate vaccine should shortly begin Phase III testing in Nepal and the Philippines; we hope that the work supported by this donation will "pave the way" for campaigns to eradicate typhoid in heavily afflicted countries.

Support for IVI's laboratories will mean that our pipeline of candidate vaccines will be more robust, and we hope not only for success in our "3d" vaccine (following on the oral cholera vaccine and typhoid conjugate vaccine) but also vaccines 4, 5, and 6!

Thank you for your belief in the power of vaccines, and for your faith in IVI, Korea's great experiment and amazing inspiration. With you and our strong supporters in the KSC, IVI will continue to grow in accomplishments and impact. We look forward to a lasting partnership and friendship with you, Prof. Sung and Mrs. Lee, and we at IVI are strengthened and inspired by your support.